Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Rimawi MF, et al. Among authors: weigelt b. Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7. Breast Cancer Res Treat. 2018. PMID: 29110152 Free PMC article. Clinical Trial.
A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks.
Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah TM, Green AR, Mukta R, Blamey R, Paish EC, Rees RC, Ellis IO, Ball GR. Lancashire LJ, et al. Among authors: weigelt b. Breast Cancer Res Treat. 2010 Feb;120(1):83-93. doi: 10.1007/s10549-009-0378-1. Epub 2009 Apr 4. Breast Cancer Res Treat. 2010. PMID: 19347577
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS. Natrajan R, et al. Among authors: weigelt b. Breast Cancer Res Treat. 2010 Jun;121(3):575-89. doi: 10.1007/s10549-009-0501-3. Epub 2009 Aug 18. Breast Cancer Res Treat. 2010. PMID: 19688261
342 results